Search
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.
Estradiol acetate
go.drugbank.com/drugs/DB13952ApprovedVet approvedThe primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. … Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84].
Amineptine
go.drugbank.com/drugs/DB04836ApprovedIllicitWithdrawnThe Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeHuman Rho(D) immune globulin
go.drugbank.com/drugs/DB11597ApprovedHuman Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). … It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults.
Categories: Human Immunoglobulin GBentoquatam
go.drugbank.com/drugs/DB00516ApprovedBentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin. … Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak.
Ifosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Products: UROMIDA® 2 G, HOLOXAN®2 G.Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalElevated levels of eosinophils increase the risk for asthma exacerbations, including both allergic forms and nonallergic forms of asthma where eosinophilia is prominent. … Inflammation-predominant asthma, which is chatacterized by eosinophilic infiltration of airway mucosa and elevated levels of eosinophils in the blood, sputum and BAL fluid, is associated with an increased
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalbinding at the ATP domain of the epidermal growth factor receptor family kinase domains. … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.
Products: Vizimpro 30 mg Film-Coated Tablets, Vizimpro 15 mg Film-Coated TabletsImdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigational[A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L39130,L39135] Full safety and efficacy data on imdevimab are not yet available, and further evaluation of this investigational therapy will continue.[L23529,L23539,L14303]
Lubiprostone
go.drugbank.com/drugs/DB01046ApprovedInvestigationalA prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastrointestinal epithelial cells. … Activation of these channels promotes the secretion of a chloride-rich fluid that soften the stool, increase gastrointestinal motility, and induce spontaneous bowel movements (SBM).